Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-7 BI 764532 plus chemotherapy in advanced neuroendocrine carcinoma
NL-OMON59385Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of obrixtamig in extrapulmonary neuroendocrine carcinoma (EPNEC), neuroendocrine carcinoma of unknown primary origin (CUP-NEC) and large cell neuroendocrine carcinoma (LCNEC), sponsored by Boehringer Ingelheim. Started Apr 2025; status: active, not recruiting.
02
Drugs
obrixtamig
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)neuroendocrine carcinoma of unknown primary origin (CUP-NEC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on NL-OMON59385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59385.